Medscape Nets $17.3 Million Through Private Investors

Article

The new year is already proving profitable for Medscape (formerly Medicalogic/Medscape), which has begun referring to itself as a provider of digital health record technologies (versus EMRs) and online health information. The company has signed a

The new year is already proving profitable for Medscape (formerly Medicalogic/Medscape), which has begun referring to itself as a provider of digital health record technologies (versus EMRs) and online health information. The company has signed a definitive agreement with a group of investors for a $17.3 million capital investment. The financing involves issuing 5.7 million shares of preferred stock at $3 per share, with warrants to purchase 4.4 million shares of common stock at $0.01 per share. The deal coincides with the appointment of Donald Bloodworth as Medscape's chief financial officer.

In related news, Medscape has signed its first digital health agreement, with Glaxo Wellcome. The educational initiative will create asthma-specific sites and disease management tools on medscape.com and cbshealthwatch.com, two Web sites produced by Medscape.

Recent Videos
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
Related Content
© 2025 MJH Life Sciences

All rights reserved.